News about Global Pharma

Piramal Alternatives Announces Investment of INR 110 Crore in Biodeal

Piramal Alternatives has made a significant investment of INR 110 Crore in Biodeal Pharmaceuticals Ltd., a leading contract development and manufacturing company, facilitated through convertible instruments from its Performing Credit Fund.

Global Pharma | 08/04/2024 | By Aishwarya |  655

Freudenberg Group to Expand in India with INR 350 Crore Investment

Freudenberg Group, a global technology conglomerate, has reported record growth in revenues and operating profits for the financial year 2023.

Global Pharma | 08/04/2024 | By Aishwarya |  989

Gland Pharma Granted USFDA Approval for Eribulin Mesylate Injection, Anticipates Market Launch

This approval marks a key moment for Gland Pharma as the product is anticipated to be the first generic approval on the market.

Global Pharma | 08/04/2024 | By Abha |  536

FDA Approves Expanded Indication for Abecma in Multiple Myeloma Treatment

Abecma, administered as a one-time infusion, demonstrates a progression-free survival benefit three times that of standard regimens in relapsed or refractory multiple myeloma.

Global Pharma | 08/04/2024 | By Abha |  605

Aurobindo Pharma Appoints T. Vijaya Kumar as President, R&D

Aurobindo Pharma has announced the appointment of T. Vijaya Kumar as President, R&D (Specialty Drug Delivery).

Global Pharma | 08/04/2024 | By Aishwarya |  1193

Cardio Diagnostics Enters Into Nationwide Telehealth Agreement with Navierre

This collaboration aims to significantly expand access to Cardio Diagnostics' industry-leading, AI-enabled precision cardiovascular diagnostic tests.

Global Pharma | 06/04/2024 | By Manvi |  470

Sebia Receives US FDA Clearance for CAPILLARYS 3 DBS Devices

This offer provides laboratories a gain in operational efficiency with high throughput and a full traceability from DBS card up to the result through a cyber-secured environment.

Global Pharma | 06/04/2024 | By Manvi |  478

Life Molecular Imaging and SOFIE Expand Partnership to Distribute Neuraceq PET Imaging Agent

Neuraceq® is an FDA-approved imaging agent used to detect beta-amyloid plaques in the brains of adult patients with cognitive impairment undergoing evaluation for Alzheimer's disease and other cognitive decline causes.

Global Pharma | 06/04/2024 | By Abha |  666

Johnson & Johnson Receives FDA Approval for CARVYKTI for Multiple Myeloma Treatment

With this advancement, CARVYKTI® becomes the first and only B-cell maturation antigen (BCMA)-targeted therapy approved for multiple myeloma treatment as early as the first relapse.

Global Pharma | 06/04/2024 | By Abha |  745

CDL Nuclear Technologies Introduces New Mobile Cardiac PET/CT Trailer

This cutting-edge mobile solution is designed to revolutionize cardiac care by directly providing state-of-the-art cardiac PET/CT imaging services to medical facilities on their schedule.

Global Pharma | 05/04/2024 | By Manvi |  412